Click the button below to contact us or submit your feedback about this product.
ImmunoArrayᵀᴹ Cancer and Tumor-Related Autoantibody Detection Service (CAT#: NA-0726-FY16)
Developed by Creative Biolabs, the Cancer and Tumor-Related Autoantibody Detection Service utilizes an advanced, high-sensitivity protein microarray platform to profile autoantibody signatures against 120 literature-backed tumor antigens. By immobilizing purified proteins onto glass slides, this high-throughput, low-sample-rate service allows researchers to monitor immune reactions during cancer progression and immunotherapy. It serves as a powerful tool for translational medicine, aiding in the discovery of clinically valuable antibody biomarkers, understanding disease mechanisms, and building multi-parametric models for early diagnostics, prognosis, and treatment assessment.
| Specifications | |
|---|---|
| Size | 16-sample format per slide; features advanced multiplexing capable of profiling>120 targets per well (encompassing the 120 cancer/tumor-specific antigens). |
| Throughput Level | High-throughput (processes 16 samples per slide simultaneously, with support for parallel operations across multiple slides). |
| Protein Count | Up to 120 purified proteins/antigens. |
| Proteome Coverage | Focused oncology panel consisting of 120 purified proteins thoroughly reviewed in literature and established as being specifically associated with various types of cancers and tumor diseases. |
| Arraying Technology | High-sensitivity antigen microarray technology (protein microarray) where protein molecules are orderly immobilized as ligands onto the solid surface of glass slides; interactions are captured via fluorescently labeled components and quantified using a fluorescence scanner. |
| Features | High Multiplexing: Screens>120 autoantibodies simultaneously in a single well, far outperforming traditional single-target ELISA methods. Ultra-low Sample Volume: Requires only 5 μL of serum or other body fluids, keeping sample consumption to an absolute minimum. High Flexibility: Capable of combining diverse antigen matrices (proteins, peptides, nucleic acids) to detect distinct antibody types and subclasses. High Sensitivity & Wide Dynamic Range: Delivers a broad signal dynamic range spanning from 1 to 65000. Cost-Effective: Maximizes research budgets by costing less than 1/10 of traditional ELISA kits. Semi-Quantitative: Allows relative quantification based on established standard curves. |
| Application Fields | Oncology & Immunotherapy: High-efficiency detection of autoantibodies in cancer patients, particularly for monitoring immune responses and toxicity in individuals undergoing immunomodulatory therapies. Autoimmune & Systemic Diseases: Profiling of conditions such as SLE, RA, diabetes, MCTD, Sjögren's syndrome, scleroderma, polymyositis, dermatomyositis, etc. Translational & Clinical Research: Large-scale immune monitoring across allergic diseases, infectious diseases, neurological impairments, vaccine R&D/post-vaccination monitoring (e.g., SARS-CoV-2, RSV, influenza), organ transplantation evaluation, drug screening, and clinical trials. |
DatasheetFor Research Use Only | Not For Clinical Use
Related products
- ImmunoArrayᵀᴹ Extractable Nuclear Antigen (ENA) and Antinuclear Antibody (ANA) Detection Service (32 Antigens) (CAT#: NA-0726-FY25)
- ImmunoArrayᵀᴹ Kidney Disease-Related Autoantibody Detection Microarray Service (51-Antigen Array) (CAT#: NA-0726-FY13)
- ImmunoArrayᵀᴹ Oligomannose Microarray (CAT#: NA-0726-FY39)
- ImmunoArrayᵀᴹ N-Glycan Microarray (CAT#: NA-0726-FY30)
- ImmunoArrayᵀᴹ Human Proteome Microarray (CAT#: NA-0526-FY1)
- ImmunoArrayᵀᴹ Autoimmune Infertility-Associated Autoantibody Detection Service/Antigen Microarray (CAT#: NA-0726-FY5)
- ImmunoArrayᵀᴹ Antiphospholipid Syndrome (APS) and Neutrophil Extracellular Traps (NETs) Related Native Protein Autoantibody Detection Service (CAT#: NA-0726-FY17)
- ImmunoArrayᵀᴹ Sialylated Glycan Microarray (CAT#: NA-0726-FY32)
Services:
Resource:
Applications:
Online Inquiry